Millipore Sigma Vibrant Logo
Atención: Nos hemos mudado. Los productos Merck Millipore ya no pueden adquirirse en MerckMillipore.comMás información
 

acetyl STAT5b


12 Results Búsqueda avanzada  
Mostrar

Acote sus resultados Utilice los filtros siguientes para refinar su búsqueda

Tipo de documento

  • (8)
  • (1)
¿No encuentra lo que está buscando?
Póngase en contacto con
el Servicio de Atención
al Cliente

 
¿Necesita ayuda para encontrar un documento?
  • «
  • <
  • 1
  • >
  • »
  • Anti-acetyl STAT5B (Lys694) -2548063

    Tipo de documento:
    Certificado de análisis
    Número de lote:
    2548063
    Referencia del producto:
    09-007
    Nombre del producto:
    Anti-acetyl STAT5B (Lys694) Antibody
  • Anti-acetyl STAT5B (Lys701) -2792434

    Tipo de documento:
    Certificado de análisis
    Número de lote:
    2792434
    Referencia del producto:
    07-1352
    Nombre del producto:
    Anti-acetyl STAT5B (Lys701) Antibody
  • Anti-acetyl STAT5B (Lys694) -2578589

    Tipo de documento:
    Certificado de análisis
    Número de lote:
    2578589
    Referencia del producto:
    09-007
    Nombre del producto:
    Anti-acetyl STAT5B (Lys694) Antibody
  • Anti-acetyl STAT5B (Lys694) -2624579

    Tipo de documento:
    Certificado de análisis
    Número de lote:
    2624579
    Referencia del producto:
    09-007
    Nombre del producto:
    Anti-acetyl STAT5B (Lys694) Antibody
  • Anti-acetyl STAT5B (Lys701) - 2564030

    Tipo de documento:
    Certificado de análisis
    Número de lote:
    2564030
    Referencia del producto:
    07-1352
    Nombre del producto:
    Anti-acetyl STAT5B (Lys701) Antibody
  • p53 mutants induce transcription of NF-κB2 in H1299 cells through CBP and STAT binding on the NF-κB2 promoter and gain of function activity. 22198284

    Cancer cells with p53 mutations, in general, grow more aggressively than those with wild-type p53 and show gain of function (GOF) phenotypes such as increased growth rate, enhanced resistance to chemotherapeutic drugs, increased cell motility and tumorigenicity; although the mechanism for this function remains unknown. In this communication we report that p53-mediated NF-κB2 up-regulation significantly contributes to the aggressive oncogenic behavior of cancer cells. Lowering the level of mutant p53 in a number of cancer cell lines resulted in a loss of GOF phenotypes directly implicating p53 mutants in the process. RNAi against NF-κB2 in naturally occurring cancer cell lines also lowers GOF activities. In H1299 cells expressing mutant p53, chromatin immunoprecipitation (ChIP) assays indicate that mutant p53 induces histone acetylation at specific sites on the regulatory regions of its target genes. ChIP assays using antibodies against transcription factors putatively capable of interacting with the NF-κB2 promoter show increased interaction of CBP and STAT2 in the presence of mutant p53. Thus, we propose that in H1299 cells, mutant p53 elevates expression of genes capable of enhancing cell proliferation, motility, and tumorigenicity by inducing acetylation of histones via recruitment of CBP and STAT2 on the promoters causing CBP-mediated histone acetylation.
    Tipo de documento:
    Referencia
    Referencia del producto:
    17-615
    Nombre del producto:
    ChIPAb+ Acetyl-Histone H3 - ChIP Validated Antibody and Primer Set
  • «
  • <
  • 1
  • >
  • »